Overview
Corporate Profile
Gamida Cell is an advanced cell therapy company committed to finding cures for patients with cancer and other serious diseases. We harness our NAM-enabled technology platform to create therapies with the potential to improve the course of cancer care.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
Latest News
View All
Jan 07, 2022
Gamida Cell Announces Data to be Presented at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings
Read More
Dec 13, 2021
Gamida Cell Presents Two-Year Survival Data for GDA-201 and Resource Utilization Analysis for Omidubicel at 63rd ASH Annual Meeting
Read More
Nov 16, 2021
Gamida Cell to Present Corporate Highlights at Multiple Upcoming Investor Conferences
Read More
Nov 15, 2021
Gamida Cell Reports Third Quarter 2021 Financial Results and Provides Company Update
Read More
Nov 09, 2021
Gamida Cell Presents New Data on Nicotinamide-Enabled NK Cell Therapy at Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting
Read More
Nov 08, 2021
Gamida Cell Announces the Date of Its Third Quarter 2021 Financial Results and Webcast
Read More
Nov 04, 2021
Gamida Cell Presents Data on its NAM-Enabled NK Cell Therapies at Protein & Antibody Engineering Summit (PEGS) Europe
Read More
Oct 26, 2021
Gamida Cell to Present NAM-Enabled, Genetically Modified NK Cell Therapy Pipeline and Update on GDA-201 at Today’s Virtual R&D Day
Read More
Oct 19, 2021
Gamida Cell to Present at Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting
Read More
Sep 28, 2021
Gamida Cell to Host Virtual Event Highlighting GDA-201 and NAM-Enabled, Genetically Modified NK Cell Therapy Pipeline
Read More
Sep 02, 2021
Gamida Cell to Present Corporate Highlights at Multiple Investor Conferences in September
Read More
Aug 11, 2021
Gamida Cell Reports Second Quarter 2021 Financial Results and Provides Company Update
Read More
Aug 04, 2021
Gamida Cell Announces the Date of Its Second Quarter 2021 Financial Results and Webcast
Read More
Jun 23, 2021
Gamida Cell Announces Publication in Blood, the Journal of the American Society of Hematology, of the First Pivotal Trial to Evaluate a Cell Therapy (Omidubicel) for Patients with Blood Cancer who Require an Allogeneic Stem Cell Transplant
Read More
Jun 09, 2021
Gamida Cell to Present Corporate Highlights at Multiple Investor Conferences in June
Read More
Upcoming Events
More events are coming soon.
Recent Events
Corporate Fact Sheet
Corporate Presentation
In the News
December 1, 2021
Source
Life Science Leader
December 1, 2021
Source
Life Science Leader
October 21, 2021
Source
Blood
July 20, 2021
Source
ASH Clinical News
July 16, 2021
Source
GeneTherapyLive
June 23, 2021
Source
Cell & Gene
June 22, 2021
Source
GeneTherapyLive
March 26, 2021
Source
Pharmacy Times
Investor & Media Contact
Josh Hamermesh
Chief Business Officer
Gamida Cell Ltd.
IRPR@gamida-cell.com